Lin Yong, Yuan Jun, Long Quanxin, Hu Jieli, Deng Haijun, Zhao Zhenyu, Chen Juan, Lu Mengji, Huang Ailong
Key Laboratory of Molecular Biology of Infectious Diseases (Chinese Ministry of Education), Chongqing Medical University, Chongqing, 400016, PR China.
School of Public Health and Management, Chongqing Medical University, Chongqing, 400016, PR China.
Genes Dis. 2021 Jul;8(4):484-492. doi: 10.1016/j.gendis.2020.11.005. Epub 2020 Nov 18.
To date, it remains unclear if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection exacerbates liver injury in patients with chronic hepatitis B virus (HBV) infection. In this study, we present a retrospective study of 133 hospitalized confirmed mild coronavirus disease 2019 (COVID-19) cases, including 116 patients with COVID-19 with negative serum hepatitis B antigen and 17 HBV inactive carriers with COVID-19. We found that there were no significant differences for the discharge rate or duration of hospitalization between the two groups. However, inactive HBV carriers with SARS-CoV-2 co-infection are at a higher risk of abnormal liver function tests. The enhanced liver injury induced by SARS-CoV-2 and HBV co-infection was identified as the hepatocyte type rather than the cholangiocyte type. Moreover, the inflammatory response, including abnormal lactate dehydrogenase, D-dimer and interleukin-6 production, may contribute to this injury following SARS-CoV-2 co-infection. Collectively, SARS-CoV-2 and HBV co-infection exacerbates liver function of the patients with COVID-19.
迄今为止，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）合并感染是否会加重慢性乙型肝炎病毒（HBV）感染患者的肝损伤仍不清楚。在本研究中，我们对133例住院确诊的轻度2019冠状病毒病（COVID-19）病例进行了回顾性研究，其中包括116例血清乙型肝炎抗原阴性的COVID-19患者和17例合并COVID-19的HBV非活动性携带者。我们发现两组之间的出院率或住院时间没有显著差异。然而，合并SARS-CoV-2感染的HBV非活动性携带者肝功能检查异常的风险更高。SARS-CoV-2和HBV合并感染所致的肝损伤加重被确定为肝细胞型而非胆管细胞型。此外，包括乳酸脱氢酶、D-二聚体和白细胞介素-6产生异常在内的炎症反应可能在SARS-CoV-2合并感染后导致这种损伤。总体而言，SARS-CoV-2和HBV合并感染会加重COVID-19患者的肝功能。
